Myriad Genetics (MYGN) vs Alpha Teknova (TKNO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Alpha Teknova (TKNO) has outperformed Myriad Genetics (MYGN) over the past year, gaining 77.4% versus a loss of 26.0%. Over five years, TKNO leads with a -63.6% price change compared with -79.5% for MYGN. Myriad Genetics is the larger company by market cap ($523.7 million vs $480.0 million), about 1.1 times the size, while Alpha Teknova is growing revenue faster (+7.4% vs -1.6%).
Alpha Teknova converts more of its revenue into profit, with a net margin of -42.6% versus -44.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MYGN | TKNO |
|---|---|---|
| Share price | $5.46 | $7.63 |
| Market cap | $523.74M | $479.95M |
| 1-day change | -1.44% | -2.30% |
| YTD return | -11.22% | +100.79% |
| 1-year return | -26.02% | +77.44% |
| 5-year return | -79.48% | -63.63% |
| EPS (TTM) | $-1.35 | $-0.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $824.50M | $40.52M |
| Revenue growth (YoY) | -1.56% | +7.35% |
| Net income (latest FY) | $-365.90M | $-17.26M |
| Gross margin | 69.93% | 33.17% |
| Operating margin | -46.96% | -41.90% |
| Net margin | -44.38% | -42.59% |
| 52-week high | $8.09 | $9.48 |
| 52-week low | $2.74 | $1.91 |
| Distance from 52-week high | -32.51% | -19.51% |
| Analyst consensus | hold | none |
| Avg. price target upside | +8.06% | +28.83% |
| Average volume | 2.26M | 437.31K |
| Shares outstanding | 95.92M | 62.90M |
| Employees | 2,700 | 158 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TKNO has outperformed MYGN by 103.5 percentage points over the past year.
- Alpha Teknova grew revenue faster in its latest fiscal year (+7.35% vs -1.56%).
About Myriad Genetics
MYGN stock →Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. It offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 2,700 employees
About Alpha Teknova
TKNO stock →Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 158 employees
MYGN vs TKNO FAQ
Which is bigger, Myriad Genetics or Alpha Teknova?
Myriad Genetics (MYGN) is larger, with a market capitalization of $523.74M compared with $479.95M for Alpha Teknova (TKNO).
Which stock has performed better over the past year, MYGN or TKNO?
TKNO returned +77.44% over the past 12 months, compared with -26.02% for MYGN (price return, excluding dividends). Past performance does not predict future results.
Are Myriad Genetics and Alpha Teknova in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.